Indications
Sodium zirconium cyclosilicate (ZS-9) is indicated for the treatment of hyperkalemia in adults. It should not be used as an emergency treatment for life-threatening hyperkalemia due to its delayed onset of action. 1 Patiromer and sodium polystyrene sulfonate share this indication with sodium zirconium cyclosilicate, and sodium polystyrene sulfonate is also approved for use in pediatric patients. [2] [3] [4] [5] Hyperkalemia is a potentially life-threatening metabolic condition caused by inability of the kidneys to excrete potassium, impaired uptake of potassium into cells, increased potassium intake, or a combination of these factors. Contributing causes can include severe heart failure, defects in renal tubular mechanisms, poor renal perfusion, or medications (eg, renin-angiotensin-aldosterone system [RAAS] inhibitors such as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, aldosterone antagonists, and potassium-sparing diuretics). Hyperkalemia is defined as an elevated serum potassium level above 5 mmol/L (5 mEq/L) and is typically classified by severity (mild [K+ 5-6 mmol/L], moderate [K+ 6.1-6.9 mmol/L], and severe [K+ 7 mmol/L and higher, electrocardiogram (ECG) changes, or the presence of symptoms]). The symptoms of hyperkalemia are nonspecific and can include muscle weakness, flaccid paralysis, nausea, palpitations, arrhythmias, and paresthesias. [6] [7] [8] [9] Treatment of severe hyperkalemia can include administration of intravenous (IV) calcium salts, thiazide or loop diuretics, hemodialysis, and nonabsorbable potassium-binding agents (eg, sodium polystyrene sulfonate). 6, [8] [9] [10] Sodium polystyrene sulfonate has been used for decades to lower serum potassium levels, especially in hospitalized patients. Sodium polystyrene sulfonate is a nonselective cation exchange resin; the resin releases the sodium and then binds the potassium, but may also bind other cations (eg, magnesium, aluminum). The nonabsorbable resin complex (cation plus resin) is then eliminated with bowel movements. 6, 8, 9 However, sodium polystyrene sulfonate tends to be poorly tolerated, should not be used in salt-sensitive patients, and can cause severe constipation. 11 Patiromer, another nonabsorbable polymer that binds potassium and magnesium in the gastrointestinal (GI) tract, does not require use of a cathartic. 9, 12, 13 Asymptomatic hyperkalemia caused by RAAS inhibitors is generally managed by adjustment in dosing, adherence to a low-potassium diet, reduction or removal of salt substitutes that contain potassium, and discontinuation of drugs that impair the excretion of potassium in the kidney (eg, nonsteroidal anti-inflammatory drugs, betablockers, cyclosporine, tacrolimus, ketoconazole, potassiumsparing diuretics). Treatment with thiazide or loop diuretics is recommended, especially for patients with renal impairment. In patients with chronic kidney disease (CKD) and metabolic acidosis, sodium bicarbonate administration may Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.
be useful in decreasing serum potassium concentration. Long-term use of polystyrene sulfonate is generally not tolerated and is not recommended. 10 Studies are planned to assess the use of sodium zirconium cyclosilicate to intensify RAAS inhibitor therapy in patients with heart failure and hyperkalemia or who are at high risk of developing hyperkalemia.
14 A study is also ongoing to assess inclusion of sodium zirconium cyclosilicate as part of a regimen with insulin and glucose to lower potassium levels in patients with potassium levels of 6 mmol/L or greater.
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Clinical Pharmacology
Sodium zirconium cyclosilicate is a nonabsorbed, potassium-binding, inorganic cation exchange crystalline compound formulated as an insoluble, odorless, and tasteless white powder. 1, 11 It does not expand when mixed with water, unlike sodium polystyrene sulfonate, which expands to 80% to 100% of its original volume. 16, 17 As a microporous member of the zirconium silicate family of compounds, sodium zirconium cyclosilicate captures potassium through a process mimicking the action of physiologic potassium channels. Structurally, it is composed of octahedrally and tetrahedrally oxygen-coordinated zirconium and silicon atoms. Shared oxygen atoms act like bridges between the units, forming an electrostatically charged microporous cubic structure. 
11
Sodium zirconium cyclosilicate exhibits potassium uptake over the range of pH values found in the GI tract. At low pH, such as that found in gastric fluid (pH of 1.2), there is rapid uptake followed by a reversal. As pH increases, K+ uptake is rapid and sustained. Potassium uptake is expected to begin in the lower pH of the stomach, and uptake increases as the compound passes through the GI tract due to higher potassium concentrations and higher pH. 11 In clinical trials, serum potassium declined within 1 hour of the first dose and was normalized within a median of 2.2 hours.
11 Sodium zirconium cyclosilicate binds potassium, including dietary potassium, throughout the GI tract. 16 In patients with hyperkalemia treated with sodium zirconium cyclosilicate 10 g 3 times daily for up to 48 hours, reductions in serum potassium were observed 1 hour after initiation of therapy and concentrations continued to decline over the 48-hour treatment period. Patients with higher starting potassium levels or receiving a higher dose had greater reductions in serum potassium. Administration of sodium zirconium cyclosilicate was also associated with a small, dose-dependent increase in serum bicarbonate concentrations; the significance of this finding is unclear.
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Pharmacokinetics
Sodium zirconium cyclosilicate is not absorbed in the GI tract. 11 Zirconium levels have not been observed to differ between treated and untreated patients. Comments: Evidence supporting one form of treatment for acute hyperkalemia over another is poor. Data are poor or lacking regarding IV calcium, sodium bicarbonate, fluids, and diuretics. Insulin-glucose infusion is the most effective treatment in lowering serum potassium. The use of beta agonists may be effective in some patients. Potassium exchange resins are often used, but efficacy of short-term treatment is limited because of slow onset of action.
Studies
Drug: Sodium Zirconium Cyclosilicate vs Placebo Reference: Packham DK, et al, 2015 19 Study Design: Phase 3, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, international, multicenter study Study Funding: ZS Pharma Patients: 753 adults with serum potassium level of 5 to 6.5 mmol/L. Mean age was 65 years (range, 22-93 years); 60% of patients were male and 86% were white. Inclusion criteria did not specify characteristics predisposing patients to hyperkalemia; however, 74.5% had an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m 2 , 66.7% were receiving RAAS inhibitors, 59.9% had diabetes, and 39.8% had a history of heart failure. Patients were enrolled at sites in the United States, Australia, and South Africa. Intervention: Sodium zirconium cyclosilicate 1.25, 2.5, 5, or 10 g or placebo was administered 3 times daily with meals for the first 48 hours (initial phase). Patients with a serum potassium level of 3.5 to 4.9 mmol/L at 48 hours were randomized to receive the same dose of sodium zirconium cyclosilicate or placebo once daily before breakfast on days 3 to 14 (maintenance phase). Those treated with placebo during the initial phase were randomized to receive sodium zirconium cyclosilicate 1.25 or 2.5 g in the maintenance phase. All concomitant medications, including diuretics, RAAS inhibitors, and antidiabetic therapies, were continued throughout the study, and no dietary restrictions were required.
Results
Primary End Point(s)
• • Reduction in serum potassium, measured as the exponential rate of change in mean serum potassium level from baseline per hour during the first 48 hours of treatment, was 0.11% per hour with sodium zirconium cyclosilicate 1.25 g, 0.16% per hour with the 2.5 g dose, 0.21% per hour with the 5 g dose, and 0.3% per hour with the 10 g dose, compared with 0.09% per hour with placebo (P < .001 for the 3 highest doses vs placebo; the difference in rate was not significant at the lowest dose compared with placebo). At 1 hour after the first dose, the reduction in serum potassium from baseline was 0.11 mmol/L with sodium zirconium cyclosilicate 10 g, compared with an increase of 0.01 mmol/L in the placebo group (P = .009).
Secondary End Point(s)
• • At 48 hours, mean reduction in serum potassium was 0.46 mmol/L in the 2.5 g group, 0.54 mmol/L in the 5 g group, and 0.73 mmol/L in the 10 g group, compared with a mean reduction of 0.25 mmol/L in the placebo group (P < .001 for all comparisons vs placebo). • • On average, normokalemia was achieved within 48 hours in the sodium zirconium cyclosilicate 2.5 g, 5 g, and 10 g groups (P < .001 for all comparisons vs placebo). Normokalemia was maintained in patients continuing once-daily sodium zirconium cyclosilicate, while hyperkalemia returned in those switched to placebo. Sodium zirconium cyclosilicate 5 and 10 g doses were superior to placebo in maintaining normokalemia (P = .008 and P < .001, respectively). The mean exponential rate of change was an increase of 0.14% per hour in the sodium zirconium cyclosilicate 10 g group compared with an increase of 1.04% per hour in the respective placebo group (P < .001), and an increase of 0.09% per hour in the 5 g group compared with an increase of 0.47% per hour in the respective placebo group (P = .008). After discontinuation of the 10 g dose on day 15, hyperkalemia returned within 1 week.
Other End Point(s)
• • In 45 patients in this study and the subsequent hyperkalemia randomized intervention multidose ZS-9 maintenance (HARMONIZE) study who had baseline serum potassium levels of at least 6 mmol/L (mean, 6.3 mmol/L; range, 6.1-7.2 mmol/L), the initial sodium zirconium cyclosilicate 10 g dose was associated with a 0.4 mmol/L reduction at 1 hour, a 0.6 mmol/L reduction at 2 hours, and a 0.7 mmol/L reduction at 4 hours (P < .001 for each comparison vs baseline). The median time to reach a serum potassium level of less than 6 mmol/L was 1.07 hours. The median time to reach a serum potassium level of 5.5 mmol/L or less was 4 hours. 20 • • In a subgroup analysis, normalization of serum potassium to 3.5 to 4.9 mmol/L was observed in both the 5 g and 10 g treatment groups, regardless of baseline potassium level, eGFR, RAAS inhibitor use, or history of heart failure, CKD, or diabetes. • • An additional subgroup analysis found that serum potassium was reduced and maintained in heart failure patients with hyperkalemia who were not receiving RAAS inhibitors at baseline. Further studies are necessary to determine whether long-term therapy in such patients would allow for RAAS inhibitor therapy to optimize heart failure management.
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Comments: Results demonstrated a rapid reduction in potassium levels at the highest doses, with reductions within 1 hour of the first dose and normalization of potassium levels within 48 hours. Long-term results were not assessed, but results from subgroup analyses suggest normalization of potassium levels may enable RAAS inhibitor use in a broader range of patients who are currently unable to tolerate such therapy because of hyperkalemia. 21, 22 Further long-term studies are necessary to determine whether therapy with sodium zirconium cyclosilicate would enable broader use of RAAS inhibitors or improve long-term clinical outcomes. Limitations: This was a short-term study with no active control. Patients with potassium levels greater than 6.5 mmol/L were excluded, as were patients with ECG changes associated with hyperkalemia. Reference: Kosiborod M, et al, 2014(HARMONIZE study) 16 Study Design: Phase 3, randomized, double-blind, placebocontrolled, parallel-group, international, multicenter study Study Funding: ZS Pharma Patients: 258 ambulatory patients with hyperkalemia (serum potassium level 5.1 mmol/L or greater). Mean age was 64 years; 58% of patients were male and 83% were white. Inclusion criteria did not specify characteristics predisposing patients to hyperkalemia; however, 70% were receiving RAAS inhibitors, 66% had CKD, 66% had diabetes, and 36% had heart failure. Patients were excluded if they had pseudohyperkalemia, cardiac arrhythmias requiring immediate treatment, diabetic ketoacidosis, or other severe medical conditions placing them at risk, or if they required dialysis, were receiving sodium polystyrene sulfonate or lactulose, or were pregnant.
Patients were enrolled at sites in the United States (80%), Australia (8%), and South Africa (12%). Intervention: Sodium zirconium cyclosilicate 10 g 3 times daily for 48 hours was administered to 258 patients in an open-label phase; 237 patients who achieved normokalemia (potassium level of 3.5-5 mmol/L) at the end of the open-label phase were randomized (4: 
Results
Primary End Point(s)
•
Secondary End Point(s)
• • Serum potassium levels declined from 5.6 mmol/L at baseline to 4.5 mmol/L at 48 hours with sodium zirconium cyclosilicate 10 g 3 times daily. The median time to normalization was 2.2 hours, with 84% of patients achieving normalization by 24 hours and 98% by 48 hours. A mean reduction of 0.2 mmol/L was observed at 1 hour after the first dose, followed by reductions of 0.4 mmol/L at 2 hours, 0.5 mmol/L at 4 hours, 0.7 mmol/L at 24 hours, and 1.1 mmol/L at 48 hours (P < .001 for all vs baseline). The mean exponential rate of change at 48 hours was −0.3% per hour. • • Overall, compared with baseline, mean serum potassium level declined by 0.8 mmol/L in the 5 g group, by 1.1 mmol/L in the 10 g group, and by 1.2 mmol/L in the 15 g group, compared with a 0.4 mmol/L reduction in the placebo group (P < .001 for all vs placebo). Compared with levels at initiation of the randomized phase, mean serum potassium increased 0.3 mmol/L in the 5 g group, increased 0.1 mmol/L in the 10 g group, declined 0.1 mmol/L in the 15 g group, and increased 0.6 mmol/L in the placebo group at 29 days (P = .007 for sodium zirconium cyclosilicate 5 g and P < .001 for sodium zirconium cyclosilicate 10 and 15 g vs placebo).
• • The proportion of patients with normal potassium levels at the end of the randomized phase (day 29) was greater with each sodium zirconium cyclosilicate dose compared with placebo (71% [P = .01] with the 5 g dose, 76% [P = .002] with the 10 g dose, and 85% [P < .001] with the 15 g dose, compared to 48% with placebo). • • A mean serum potassium level of less than 5.1 mmol/L during days 8 to 29 was achieved in 80% of patients in the 5 g group, 90% of the 10 g group, and 94% of the 15 g group, compared with 46% with placebo (P < .001 for each dose vs placebo). • • Median time to first hyperkalemic measure was 14 days in the 5 g group (P = .002), 28 days in the 10 g group (P < .001), and not reached in the 15 g group (P < .001), compared with 7 days in the placebo group. Median time to return to baseline potassium levels was 29 days in the 5 g group (P = .006) and was not reached in the 10 g and 15 g groups (P < .001), compared with 19 days in the placebo group.
Other End Point(s)
occurred in 10% of patients treated with sodium zirconium cyclosilicate 10 g and in 11% treated with sodium zirconium cyclosilicate 15 g, compared with 0% of patients in the sodium zirconium cyclosilicate 5 g and placebo groups; however, all cases resolved with dosage reduction. No patients developed severe hypokalemia. • • In a subgroup analysis of 87 patients with heart failure treated in the 29-day randomized phase, 60 of whom were also receiving an RAAS inhibitor, treated patients were able to maintain lower potassium levels (4.7 mmol/L with the 5 g dose, 4.5 mmol/L with the 10 g dose, and 4.4 mmol/L with the 15 g dose) than placebo-treated patients (5.2 mmol/L; P < .01 for each dose vs placebo). Normokalemia was maintained in 83%, 89%, and 92% of these patients, respectively, compared with 40% in the placebo group (P < .01 for each dose vs placebo).
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• • Reduced potassium levels were also maintained with all 3 doses compared with placebo in subgroup analyses of patients with CKD receiving RAAS inhibitor therapy and patients with stage 4 or 5 CKD.
24,25
Comments: The majority of patients who achieved a reduction in potassium levels with short-term therapy were able to maintain normokalemia with continued daily administration for 29 days. Those who completed the study were eligible to continue treatment with sodium zirconium cyclosilicate, taken just before breakfast, in an open-label extension study for up to 11 months. Effects on serum potassium were maintained during the study extension. 1 Results of subgroup analyses suggest normalization of potassium levels may enable RAAS inhibitor use in a broader range of patients who are currently unable to tolerate such therapy because of hyperkalemia. [23] [24] [25] Further long-term studies are necessary to determine whether therapy with sodium zirconium cyclosilicate would enable broader use of RAAS inhibitors or improve long-term clinical outcomes. Limitations: This study was of short duration and included only potassium end points rather than clinical end points. Reference: Ash SR, et al, 2015 26 Study Design: Phase 2, randomized, double-blind, placebo-controlled, dose-finding, multicenter study Study Funding: ZS Pharma Patients: 90 patients with stable stage 3 CKD and hyperkalemia (serum potassium level, 5-6 mmol/L). Mean age was approximately 70 years; 58% of patients were male, 98% were white, 56% had a history of diabetes, and 62% were receiving an RAAS inhibitor. Patients were enrolled at 9 sites in the United States. Intervention: Sodium zirconium cyclosilicate 0.3 g (n = 12), 3 g (n = 24), 10 g (n = 24), or placebo (n = 30) was administered 3 times daily with regular meals, for a minimum of 6 doses over a 48-hour period as initial management. No patient in the sodium zirconium cyclosilicate 10 g group required treatment beyond 48 hours. Continued treatment was required on day 3 (doses administered, 7-9) for placebo (30%) and sodium zirconium cyclosilicate 0.3 g (16.7%) and 3 g (12.5%) patients, and on day 4 (doses administered, 10-12) for placebo (10%) and sodium zirconium cyclosilicate 0.3 g (8.3%) patients.
Results
Primary End Point(s)
• • Rate of serum potassium decline in the first 48 hours was greater with sodium zirconium cyclosilicate 3 and 10 g compared with placebo (P < .001). Mean serum potassium declined 0.11 mmol/L at 1 hour after the first dose in the 10 g group (P = .02 vs placebo).
The maximum reduction was 0.92 mmol/L at 38 hours (P < .001) in the 10 g group.
Secondary End Point(s)
• • At 38 hours, 41.7% of patients in the 10 g group had a reduction in serum potassium of 1 mmol/L or greater, compared with 3.4% of patients receiving placebo.
Comments:
The study provided justification for additional studies assessing sodium zirconium cyclosilicate 10 g administered 3 times daily for 2 days in the initial management of hyperkalemia. A larger phase 3 study evaluating sodium zirconium cyclosilicate in the treatment of hyperkalemia in patients on hemodialysis is ongoing.
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Limitations: This was a small, dose-finding study. Drug: Sodium Zirconium Cyclosilicate Reference: Lokelma prescribing information, 2018 1, 28 Study Design: Open-label, multicenter study Study Funding: ZS Pharma Patients: 751 adult patients with hyperkalemia, defined as 2 consecutive potassium values (measured 60 minutes apart) of 5.1 mmol/L or greater. Mean patient age was 63.6 years, 40% were women, and the majority (83%) were white; mean baseline potassium was 5.6 mEq/L. Of the 751 patients, 746 (99%) achieved normokalemia within 72 hours and entered the maintenance phase. Intervention: During the acute phase, sodium zirconium cyclosilicate 10 g was administered 3 times daily for 24 to 72 hours. If potassium levels were normalized (3.5-5 mEq/L) within 72 hours, patients entered the extended dosing phase with an initial dosage of 5 g once daily; the dosage was adjusted, based on serum potassium level, to a minimum of 5 g every other day up to a maximum of 15 g once daily. Treatment was continued for up to 12 months. 
Results
Primary End Point(s)
Comments:
Patients were enrolled at sites in the United States, Australia, Germany, the Netherlands, Romania, South Africa, and the United Kingdom. Limitations: Limited results are summarized in the prescribing information and on ClinicalTrials.gov.
Contraindications, Warnings, and Precautions
Contraindications
The prescribing information states that there are no contraindications to use of sodium zirconium cyclosilicate.
Although not stated in the product labeling, hypersensitivity to sodium zirconium cyclosilicate should be considered. Table 1 compares the labeled contraindications, warnings, and precautions associated with potassium-binding therapies.
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Warnings and Precautions
Sodium zirconium cyclosilicate should not be used in patients with severe constipation or bowel obstruction or impaction, including postoperative bowel motility disorders, because it has not been studied in patients with these conditions and may be ineffective or worsen GI conditions. 1 Edema has been observed in clinical trials with sodium zirconium cyclosilicate. Edema was generally mild to moderate in severity and occurred more commonly in patients treated with 15 g once daily. Each 5 g dose of sodium zirconium cyclosilicate contains approximately 400 mg of sodium. Patients should be monitored for edema, particularly those who should restrict their sodium intake or who are prone to fluid overload (eg, heart failure, renal disease). Patients should be advised to adjust their sodium intake and increase diuretic doses as needed. 1 Sodium zirconium cyclosilicate is not absorbed systemically following oral administration; therefore, maternal use is not expected to result in fetal exposure to the drug, and breastfeeding is not expected to result in exposure of the infant to the drug. 1 Safety and efficacy of sodium zirconium cyclosilicate have not been established in pediatric patients. 1 A required postmarketing study evaluating the safety, tolerability, and pharmacodynamic effects of sodium zirconium cyclosilicate in pediatric patients 0 to 17 years of age will be completed by 2021.
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Adverse Reactions
The most common adverse reaction in clinical trials was edema, which was reported in 4.4% of patients receiving 5 g daily, in 5.9% receiving 10 g daily, and in 16.1% receiving 1 Interactions were not observed when sodium zirconium cyclosilicate was administered with losartan, glipizide, and levothyroxine. In addition, in vitro interactions were not observed with allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone, and ticagrelor. 
Recommended Monitoring
Serum potassium should be monitored regularly, and dosing should be adjusted as necessary to maintain potassium within 
Dosing
For the initial treatment of hyperkalemia, the recommended dosage of sodium zirconium cyclosilicate is 10 g administered 3 times daily for up to 48 hours, followed by a dosage of 10 g once daily. To maintain serum potassium levels within the normal range, the dose may be up-titrated at intervals of 1 week or longer and in increments of 5 g. For some patients, administration of lower doses or administration every other day was sufficient to maintain normokalemia and avoid hypokalemia. The recommended maintenance dosage range is from 5 g every other day to 15 g daily. 1, 16, 19 Patients should be instructed to empty the entire content of the packet(s) into a drinking glass containing approximately 3 tablespoons or more of water. The mixture should be stirred well and immediately consumed. If powder remains in the drinking glass, water should be added, and the mixture stirred again and immediately consumed; this process should be repeated until no powder remains in the glass. 1 In general, other medications should be administered at least 2 hours before or 2 hours after sodium zirconium cyclosilicate.
1 Table 2 compares the dosing and administration for sodium zirconium cyclosilicate, patiromer, and sodium polystyrene sulfonate.
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Product Availability
The New Drug Application for sodium zirconium cyclosilicate was submitted to the U.S. Food and Drug Administration (FDA) in May 2015 and approved in May 2018. 29 Sodium zirconium cyclosilicate is available as a white powder for oral suspension and supplied in 5 g and 10 g foil-lined packets in boxes containing 30 packets. 1 The packets should be stored at 15°C to 30°C (59°F-86°F). 
Drug Safety/Risk Evaluation and Mitigation Strategy (REMS)
No REMS is required for sodium zirconium cyclosilicate.
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Conclusion
Sodium zirconium cyclosilicate, a nonabsorbed, potassiumbinding, inorganic cation exchange crystalline compound that selectively entraps potassium and ammonium in the GI tract, is approved for the treatment of hyperkalemia in adults. In patients with mild to moderate hyperkalemia, it has exhibited potassium-lowering activity within 1 hour of oral administration. In patients with heart failure, CKD, or diabetes, as well as in those receiving RAAS inhibitors, it has exhibited an ability to maintain normokalemia with daily administration for up to 29 days. Sodium zirconium cyclosilicate is well tolerated with short-term administration, although edema has been frequently observed. Additional studies are necessary to determine long-term safety and efficacy.
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Administration
Take at least 2 hours before or 2 hours after other medications.
Take at least 3 hours before or 3 hours after other medications.
Administer with patient in upright position. Take at least 3 hours before or 3 hours after other oral medications.
